Fas ligand expression in human and mouse cancer cell lines; a caveat on over-reliance on mRNA data
2006

Fas Ligand Expression in Cancer Cells

Sample size: 9 publication Evidence: moderate

Author Information

Author(s): Ryan Aideen E, Lane Sinead, Shanahan Fergus, O'Connell Joe, Houston Aileen M

Primary Institution: National University of Ireland Cork (NUIC)

Hypothesis

The study aimed to comprehensively characterize FasL expression in tumors of both murine and human origin over a 72 hour time period.

Conclusion

The study found that tumor cells can express FasL protein even when FasL mRNA is absent, highlighting the need for complete analysis of FasL expression.

Supporting Evidence

  • FasL mRNA expression varied dramatically over time in all cell lines analyzed.
  • All cell lines constitutively expressed FasL protein despite variations in mRNA levels.
  • The study used multiple methods to confirm FasL expression, including RT-PCR and Western blotting.

Takeaway

Cancer cells can have a protein called FasL that helps them hide from the immune system, even when they don't have the instructions (mRNA) to make it.

Methodology

RNA and protein were extracted from six human and three mouse cancer cell lines, and FasL expression was detected using RT-PCR and Western Blotting.

Potential Biases

Potential bias due to reliance on specific antibodies for detection of FasL.

Limitations

The study focused on a limited number of cell lines and time points, which may not represent all tumor types.

Participant Demographics

The study included six human cancer cell lines and three mouse cancer cell lines.

Digital Object Identifier (DOI)

10.1186/1477-3163-5-5

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication